Finding the right reimbursement model for gene therapiesWith cell and gene therapies growing more and more important to healthcare, we sat down with Debbie Warner, Share XFinding the right reimbursement model for gene therapieshttps://pharmaphorum.com/views-and-analysis/finding-the-right-reimbursement-model-for-gene-therapies/
Century gets $250m to develop next-gen ‘off the shelf’ cancer cell therapiesCentury Therapeutics has emerged from stealth mode to develop a new generation of ‘off the shelf’ cancer cell Share XCentury gets $250m to develop next-gen ‘off the shelf’ cancer cell therapieshttps://pharmaphorum.com/news/century-gets-250m-to-develop-next-gen-off-the-shelf-cancer-cell-therapies/
Gilead highlights Yescarta survival data in ASCO updateGilead’s Kite subsidiary has reported new data from the main trial for its CAR-T Yescarta, hoping to encourage Share XGilead highlights Yescarta survival data in ASCO updatehttps://pharmaphorum.com/news/gilead-highlights-yescarta-survival-data-in-asco-update/
Mustang Bio’s first-of-a-kind CAR-T starts trialsUS biotech Mustang Bio says that an investigator-led trial of its CAR-T therapy for multiple myeloma – the Share XMustang Bio’s first-of-a-kind CAR-T starts trialshttps://pharmaphorum.com/news/mustang-bio-car-t-starts-trials/
Janssen CAR-T is Priority Medicine in EU, and moreEuropean regulators are to hasten development of Janssen’s CAR-T therapy for patients with multiple myeloma, after promising early-stage Share XJanssen CAR-T is Priority Medicine in EU, and morehttps://pharmaphorum.com/views-analysis-oncology/janssen-car-t-is-priority-medicine-in-eu-and-more/
Cell Mogrify gets £420k funding for regenerative cell therapiesUK cell therapy company Cell Mogrify has been awarded £420,000 funding from Innovate UK to accelerate its data-driven Share XCell Mogrify gets £420k funding for regenerative cell therapieshttps://pharmaphorum.com/news/cell-mogrify-gets-420k-funding-for-regenerative-cell-therapies/
How T-cell therapy saved my lifeJudy Perkins’ stage 4 cancer was eradicated after she joined a clinical trial for T-cell therapy. She shares Share XHow T-cell therapy saved my lifehttps://pharmaphorum.com/views-analysis-patients/how-t-cell-therapy-saved-my-life/
Oncology round-up: Shareholders question BMS/Celgene merger, while Merck & Co’s Keytruda keeps getting strongerWill it happen or not? There are doubts about whether the proposed $74 billion merger of cancer drug Share XOncology round-up: Shareholders question BMS/Celgene merger, while Merck & Co’s Keytruda keeps getting strongerhttps://pharmaphorum.com/views-analysis-oncology/oncology-round-up-shareholders-question-bms-celgene-merger-while-merck-cos-keytruda-keeps-getting-stronger/
Gilead expands CAR-T deal with MaxCyte, Precision files for $100m IPOIt has been a busy month already in the field of CAR-T therapy, with Gilead expanding a partnership Share XGilead expands CAR-T deal with MaxCyte, Precision files for $100m IPOhttps://pharmaphorum.com/news/gilead-expands-car-t-deal-with-maxcyte-precision-files-for-100m-ipo/
